Biogen: Phase 2 BIIB059 Study Meets Primary Endpoints in Lupus

Date : 04/12/2019 @ 00:15
Source : Dow Jones News
Stock : Biogen Inc (BIIB)
Quote : 299.39  9.87 (3.41%) @ 08:32
Biogen share price Chart
After Hours
Last Trade
Last $ 299.39 ◊ 0.00 (0.00%)

Biogen: Phase 2 BIIB059 Study Meets Primary Endpoints in Lupus

Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Biogen Charts.

By Colin Kellaher


Biogen Inc. (BIIB) on Tuesday said a Phase 2 study of its BIIB059 antibody in patients with the autoimmune disease lupus met its primary endpoints, showing statistically significant reduction of disease activity compared to placebo.

The Cambridge, Mass., biopharmaceutical company said the two-part study evaluated BIIB059 in individuals with active cutaneous lupus erythematosus, including chronic and subacute subtypes, with or without systemic manifestations, and in individuals with systemic lupus erythematosus with active joint and skin manifestations.

Biogen said the safety and tolerability profile of BIIB059 supports its continued development, adding that the study results support the company's goal of building a multi-franchise portfolio.


Write to Colin Kellaher at


(END) Dow Jones Newswires

December 03, 2019 08:00 ET (13:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Euro vs Au..
US Dollar ..
BHP Bilito..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20191205 22:25:19